Publication
Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma - the BELI(E)VE trial.
Christoph Schaefers, Cyrus Khandanpour, Mathias Hänel, Miriam Kull, Winfried Alsdorf, Abdulaziz Kamili, Ricardo Kosch, William Krüger, Stephan Bohl, Elias Karl Mai, Christof Scheid, Hermann Einsele, Monika Brüggemann, Anna Suling, Antonia Zapf, Carsten Bokemeyer, Katja Weisel, Lisa Leypoldt
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Multiple myeloma (MM) is a widely incurable B-cell malignancy that predominantly affects older adults, representing 10% of hematologic cancers. Despite advancements in therapy that have significantly extended median overall survival (OS), MM remains a clinical challenge with poor…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT05853965registry_reference1.00
Candidate 1
- cancerMultiple Myelomadictionary0.60
Registered trialsNCT05853965
Curated evidence
Evidence citing this paper (0)
Data not yet available